We hypothesized that midregional pro-A-type natriuretic peptide (MR-proANP), the stable midregional epitope of proANP, might be useful in the early diagnosis and risk stratification of patients with suspected acute myocardial infarction (AMI). In this multi-center study we measured MR-proANP, cardiac troponin T (cTnT), and high-sensitive cTnT (hs-cTnT) at presentation in 675 consecutive patients presenting to the emergency department with suspected AMI. The final diagnosis was adjudicated by 2 independent cardiologists. Patients were followed 360 days for mortality and AMI. AMI was the final diagnosis in 119 patients (18%). Median MR-proANP levels at presentation were significantly higher in patients with AMI (189 pmol/L, interquartile range 97 to 341) versus patients with another final diagnosis (83 pmol/L, 49 to 144, p < 0.001). However, neither the combination of MR-proANP with cTnT nor its combination with hs-cTnT significantly improved diagnostic accuracy as quantified by area under the receiver operating characteristic curve (0.91 vs 0.89 for cTnT alone, p = 0.086; 0.95 vs 0.96 for hs-cTnT, respectively, p = 0.02). Cumulative 360-day mortality/AMI rates were 2.4% in the first, 3.6% in the second, 9.5% in the third, and 18.8% in the fourth quartiles of MR-proANP (p < 0.001). MR-proANP (area under the curve 0.76) predicted mortality/AMI independently of and more accurately than cTnT (area under the curve 0.62), hs-cTnT (area under the curve 0.71), and Thrombolysis In Myocardial Infarction risk score (area under the curve 0.72). Net reclassification improvements offered by the additional use of MR-proANP were 0.388 (p < 0.001), 0.425 (p < 0.001), and 0.217 (p = 0.007), respectively. In conclusion, MR-proANP improves risk prediction for 360-day mortality/AMI but does not seem to help in the early diagnosis of AMI. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012; 109:1117-1123)
机构:Christchurch Sch Med & Hlth Sci, Christchurch Cardioendocrine Res Grp, Dept Med, Christchurch, New Zealand
Hillock, R. J.
Frampton, C. M.
论文数: 0引用数: 0
h-index: 0
机构:Christchurch Sch Med & Hlth Sci, Christchurch Cardioendocrine Res Grp, Dept Med, Christchurch, New Zealand
Frampton, C. M.
Yandle, T. G.
论文数: 0引用数: 0
h-index: 0
机构:Christchurch Sch Med & Hlth Sci, Christchurch Cardioendocrine Res Grp, Dept Med, Christchurch, New Zealand
Yandle, T. G.
Troughton, R. W.
论文数: 0引用数: 0
h-index: 0
机构:Christchurch Sch Med & Hlth Sci, Christchurch Cardioendocrine Res Grp, Dept Med, Christchurch, New Zealand
Troughton, R. W.
Lainchbury, J. G.
论文数: 0引用数: 0
h-index: 0
机构:Christchurch Sch Med & Hlth Sci, Christchurch Cardioendocrine Res Grp, Dept Med, Christchurch, New Zealand
Lainchbury, J. G.
Richards, A. M.
论文数: 0引用数: 0
h-index: 0
机构:
Christchurch Sch Med & Hlth Sci, Christchurch Cardioendocrine Res Grp, Dept Med, Christchurch, New ZealandChristchurch Sch Med & Hlth Sci, Christchurch Cardioendocrine Res Grp, Dept Med, Christchurch, New Zealand